Ocrelizumab: all 56 studies that test it

Page 1 of 1. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.

• A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 TherapyRecruitingNCT07609719Phase 4
• An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab TreatmentRecruitingNCT06675955Phase 3
• Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple SclerosisEnrolling by invitationNCT06495593Phase 4
• A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple SclerosisRecruitingNCT05906992Phase 3
• Ocrelizumab for Psychosis by AutoimmunityRecruitingNCT03971487Phase 1/2
• Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714RecruitingNCT03691077Phase 3
• A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple SclerosisCompletedNCT05232825Phase 3Results posted
• A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)Active, not recruitingNCT05123703Phase 3Results posted
• A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving OcrelizumabCompletedNCT04998851Phase 4Results posted
• A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During PregnancyCompletedNCT04998812Phase 4Results posted
• Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple SclerosisTerminatedNCT04925557Phase 2/3Results posted
• Ocrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.TerminatedNCT04877457Phase 4Results posted
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)Active, not recruitingNCT04548999Phase 3Results posted
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)Active, not recruitingNCT04544436Phase 3Results posted
• Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple SclerosisCompletedNCT04261790Phase 4Results posted
• A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple SclerosisActive, not recruitingNCT04075266Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple SclerosisActive, not recruitingNCT04035005Phase 3Results posted
• Short-term B-cell Depletion in Relapsing Multiple SclerosisCompletedNCT03853746Phase 4Results posted
• Efficacy of Ocrelizumab in Autoimmune EncephalitisTerminatedNCT03835728Phase 2Results posted
• This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)CompletedNCT03599245Phase 3Results posted
• Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)TerminatedNCT03085810Phase 3Results posted
• Safety of Switching From Rituximab to Ocrelizumab in MS PatientsCompletedNCT02980042Phase 3Results posted
• A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)CompletedNCT02861014Phase 3Results posted
• Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)CompletedNCT02688985Phase 3Results posted
• A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)CompletedNCT02637856Phase 3Results posted
• A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple SclerosisCompletedNCT01412333Phase 3Results posted
• A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple SclerosisCompletedNCT01247324Phase 3Results posted
• A Study of Ocrelizumab in Participants With Primary Progressive Multiple SclerosisCompletedNCT01194570Phase 3Results posted
• A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or AdalimumabTerminatedNCT00808210Phase 2Results posted
• A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple SclerosisCompletedNCT00676715Phase 2Results posted
• A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate TherapyTerminatedNCT00673920Phase 3Results posted
• A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)TerminatedNCT00626197Phase 3Results posted
• A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN)TerminatedNCT00539838Phase 3Results posted
• A Study of Ocrelizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Are Naive to Methotrexate (FILM)TerminatedNCT00485589Phase 3Results posted
• A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)TerminatedNCT00476996Phase 3Results posted
• A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)TerminatedNCT00406419Phase 3Results posted
• A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of RPH-035 and Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With ExacerbationsActive, not recruitingNCT07597668Phase 1
• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple SclerosisActive, not recruitingNCT07483450Phase 4
• Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple SclerosisActive, not recruitingNCT06847724Phase 3
• IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple SclerosisSuspendedNCT06677710Phase 1
• Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority TrialActive, not recruitingNCT05999604Phase 3
• B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple SclerosisActive, not recruitingNCT05296161Phase 4
• Ocrelizumab Discontinuation in Relapsing Multiple SclerosisActive, not recruitingNCT05285891Phase 4
• A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple SclerosisActive, not recruitingNCT05269004Phase 3
• LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMABActive, not recruitingNCT05210621Phase 3
• A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple SclerosisWithdrawnNCT05208840Phase 4
• Efficacy and Safety of Xacrel® (Ocrelizumab) in Participants With Relapsing Remitting Multiple SclerosisCompletedNCT04966338Phase 3
• Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis OnsetActive, not recruitingNCT04466150Phase 4
• Effects of Ocrevus in Relapsing Multiple SclerosisActive, not recruitingNCT04387734Phase 4
• Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With OcrelizumabCompletedNCT04377555Phase 4
• A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic SettingCompletedNCT03589105Phase 4
• A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple SclerosisActive, not recruitingNCT03523858Phase 3
• A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL)CompletedNCT02723071Phase 1/2
• A Study of Ocrelizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA)TerminatedNCT02720120Phase 1/2
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics/Pharmacodynamics (PK/PD) of Ocrelizumab in Patients With Rheumatoid ArthritisTerminatedNCT00779220Phase 2
• A Study to Evaluate the Safety of Escalating Doses of Ocrelizumab in Subjects With Rheumatoid ArthritisCompletedNCT00077870Phase 1/2

← Ocrelizumab overview